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Aim: 
This EAACI Task Force aims to provide a comprehensive and complete overview of the currently 
available tools for diagnosis of ocular allergic diseases. The key issues for inclusion are: 
 
 Describe current methods for the diagnosis of OA 
 Promote common nomenclature and procedures between different specialists 
 Review available questionnaires and create or adapt a new one 
 Available sign and symptom grading scales and create or adapt a new one easy to use for all 
specialists 
 Review the literature for potential biomarkers for OA  
 Promote a common workup for the diagnosis 
 Identify unmet needs in the diagnostic tools 




Introduction: Ocular allergy (OA) includes a group of very and less common 
hypersensitivity disorders of the ocular surface diagnosed and managed by 
ophthalmologists but also by allergists, pediatricians, rhinologists and other 
specialists. However, OA is frequently misdiagnosed and not properly managed. The 
diagnosis of OA is usually based on clinical history and signs and symptoms, with the 
support of in vivo and in vitro tests when identification of the specific allergen is 
required for patient management. To date, no specific test is available for the 
diagnosis of the whole spectrum of the different forms of OA. The lack of 
recommendations on diagnosis of OA is considered a medical need not only for 
allergists but also for ophthalmologists. 
 
Aim: This EAACI Task Force aims to provide a comprehensive and complete overview 
of the currently available tools for diagnosis of ocular allergic diseases to promote a 
common nomenclature and procedures to be used by different specialists. 
 
Results: In the present manuscript we describe current methods for the diagnosis of 
OA. Questionnaire, sign and symptom grading scales, tests and potential biomarker 
for OA are reviewed.  We also identified several unmet needs in the diagnostic tools 
to stimulate the interest, comprehension and further investigations in this subject. 
 
Conclusions: Tools and recommendations for the diagnosis of the different ocular 
allergic diseases are proposed to be used by both allergists and ophthalmologists. 
We also identified several unmet needs in the diagnostic tools to be further 





Allergic conjunctivitis and ocular allergy, [and] diagnosis / investigation / workup 
[and] imaging [and] questionnaire / quality of life / QoL [and] grading or scoring 
[and] visual function [and] tear sampling [and] biomarkers [and] differential 
diagnosis [and] psychological impact [and] tear function  
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Introduction and Current Classification of Ocular Allergy  
 
The term allergic conjunctivitis (AC) refers to a collection of ocular surface disorders 
that affects the lid and conjunctiva. IgE- and non-IgE-mediated hypersensitivity 
disorders include seasonal and perennial allergic conjunctivitis (SAC and PAC), vernal 
and atopic keratoconjunctivitis (VKC and AKC) and contact blepharoconjunctivitis 
(CBC) (1) (Table 1). These diseases are diagnosed and managed not only by 
ophthalmologists but also by allergists, pediatricians and rhinologists usually 
considering clinical history and signs and symptoms, with the support of in vivo and 
in vitro tests when identification of the specific allergic sensitization is required for 
patient management (1).  While their clinical characteristics allow a relatively 
convincing diagnosis, in their initial or chronic stages there can be some confusion as 
to which form of allergy is present. At times, pseudo-allergic forms, with clinical 
manifestations similar to allergy but with a non-allergic equivocal pathogenesis, are 
difficult to distinguish from ocular allergic forms. In fact, several ocular surface 
diseases, including tear film dysfunction, blepharitis, subacute and chronic 
infections, toxic and mechanical conjunctivitis may mimic the clinical pictures of 
ocular allergy. To date, there is no specific clinical and laboratory test suitable for the 
diagnosis and monitoring of allergic conjunctivitis. Ancillary tests, such as skin prick 
and the identification of serum specific IgE, can be useful for diagnosis and 
treatment, however it is well known that the results are often not correlated with 
the ocular disease. 
As in many other diseases, effective prevention, curative treatment and accurate, 
rapid diagnosis and particularly the lack of recommendations on diagnosis of ocular 
allergy, represent major unmet needs (2). This EAACI Task Force aims to provide a 
comprehensive and complete overview of the currently available tools for diagnosis 
of ocular allergic diseases to make recommendations concerning the diagnosis of 
ocular allergy (OA) in daily clinical practice.  
 
 
Methods   to be better explain the biblio search 
A systematic review of the literature was performed in Pubmed and Science Direct 
databases, using the following key words: Allergic Conjunctivitis or Ocular Allergy 
[AND] Diagnosis workup, Investigations, Imaging, Questionnaire / QoL, Scoring/ 
Grading, Instruments / Specific tools, Clinical, Visual function/acuity, Ocular 
sampling/Tears, Tear Function, Biomarkers, Psychological impact. 
Confounding diagnosis of terms ocular allergy (MESH): not allergic hypersentivity 
such as Stevens Johnson syndrome, graft versus host disease, were eliminated using 
a filter: NOT (Stevens OR dacryo* OR retina OR uveitis OR gvh OR optic nerve) 
If number of references reasonable, manual selection and report at the end of this 
file. If number to large, link is integrated in the table (table 2) 
 
Hand searches of the reference lists of selected studies were performed and relevant 
studies identified. Experts were contacted to suggest other studies not previously 
encountered in the database search. Studies were considered if they included 
human subjects, irrespective of age and race, and addressed diagnostic procedures, 
diagnostic utilities, irrespectively of the type of the ocular allergic disease in which 
they were performed. No time or language limitations were established. Papers 
were selected according to the information provided on the title and abstract for the 
covered topics of the review. From the ???? retrieved papers, each topic was 
reviewed by two independent experts and, finally, ???? papers were included and 
analyzed. Evidence to support each point was reviewed and a consensus decision 
was made for each chapter. As the evidence approaching a diagnostic procedure was 
scarce, some of the recommendations were based on consensus-driven proposals 




Patient’s clinical history  
 
Rationale 
The patient’s medical history is the first and a very important step in the diagnosis of 
the OA, especially in the differential diagnosis of “Red Eye” which is one of the most 
common ophthalmologic conditions (3). Well-performed anamnesis may provide 
data to help in resolving the etiology of the red eye.  
The medical history should cover types of symptoms (itching, burning, photophobia, 
type and amount of discharge, visual changes, severity of pain), unilateral or bilateral 
eye involvement, duration of symptoms, presence of allergies or systemic diseases, 
previous treatment, family history, environmental and occupational exposures, use 
of contact lenses and any type of ocular surgery (1).  
 
Signs and symptoms 
 
Ocular itching, evaluated by the patient, is the hallmark subjective symptom of 
allergic conjunctivitis. It indicates the release of histamine from conjunctival mast 
cells and the activation of H1 receptors on nerve endings (30). Ocular redness 
(hyperemia) is the primary sign of allergic conjunctivitis due to a vasodilatation. 
Photographic scales can be very useful to minimize subjective observer variability of 
conjunctival hyperemia (see later). Secondary signs and symptoms are tearing (or 
watery eyes), conjunctival chemosis, and lid swelling all evaluated by the physician.  
 
 
Itching.  It is the hallmark symptom of OA, especially if it is moderate or severe. Mild 
itching may be also observed in viral conjunctivitis and in dry eye (1). Eyelid itching is 
referred by blepharitis patients and especially if related to eyelash infestation. 
 
Tearing.     …… 
 
Hyperemia. Hyperemia is often present in ocular allergy with a typical diffuse 
location. In the situation of local hyperemia a differential diagnosis with, 
subconjunctival hemorrhage and episcleritis should be considered. 
 
Severe symptoms occur particularly in AKC and VKC although they can be sometimes 
encountered in SAC and PAC.  
Pain. Pain is not a typical symptom of the ocular allergy conditions SAC or PAC. 
However the presence of pain is a sign of corneal involvement as a complication of 
disease in VKC and AKC.  
 
Visual disturbances. The typical allergic patient may report mild blurring or normal 
vision. However the visual impairment is a sign of corneal involvement as a 
complication of VKC and AKC. 
 
Discharge.  Frequently present in OA. Both intermittent and perennial forms may 
have intermittent discharge. If it persists, dry eye or any form of tear film 
dysfunction should be considered. The type of discharge is crucial: in OA discharge is 
usually watery or serous. The mucopurulent or purulent discharge evokes infectious 
conjunctivitis. Bilateral discharge upon awaking is a sign of blepharitis. Sticky mucous 
discharge and tearing especially if associated to severe photophobia in a child are 
significant for VKC. 
 
Signs and symptoms outbreak modalities 
 
Unilateral or bilateral involvement. Bilateral involvement is typical for ocular allergy. 
It is very useful for differentiation diagnosis. However, non-symmetrical forms are 
possible. In viral conjunctivitis for example the symptoms are often unilateral at 
onset and become bilateral one or two days later.  
 
Time of onset. First symptoms of SAC and PAC appear mostly in adolescents and 
young adults (80% of patients are younger than 30 years old), but can also start in 
older patients (4). VKC usually begins in boys aged 3-12, rarely but possibly before 
the age of 3. The symptoms often disappear after puberty (5). It is observed more 
frequently in warm climates. VKC is more frequent in Mediterranean basin, Middle 
East, Far East, Africa and South America (6). In AKC, eye symptoms may appear years 
after skin involvement and appear usually at 30-50 years old (7). Overlaps or 
evolutions from VKC to AKC may occur.  
 
Duration of symptoms/Environmental and occupational exposures. One of the most 
important points in the clinical history is the duration of symptoms. SAC is caused by 
exposure to plant pollens and spores. The onset and duration of symptoms are 
limited to the pollen season in which high atmospheric concentrations of these 
allergens are reached and they recur every season although their severity may differ. 
It is self-limiting when the season is over (8). In PAC, symptoms are usually mild but 
persistent and exacerbate after increased or long-lasting exposure to allergen or 
unspecific irritating factors. The patient should be asked about symptoms after 
contact with main allergens like house dust mite, animal dander, latex or molds (9, 
10). PAC and AKC may also present with seasonal exacerbations. VKC worsens in the 
spring and summer but, if severe, the symptoms can be observed all year round.  
 
Other circumstances. Patients being diagnosed for giant papillary conjunctivitis (GPC) 
should be asked about contact lenses or ocular prostheses as well as previous ocular 
surgeries. A detailed contact lenses history should be taken (11). In CBC a detailed 
medical history has to be taken with a special attention to different substances that 
could be applied into or around the eye (medications, cosmetics etc.). If there is a 
possible work-related OA it has to be confirmed by worsening of symptoms in the 
workplace (1, 12). Some nonspecific factors like smoke, pollution or wind can 
increase symptoms of the OA diseases (10). In addition food or food additives like 
tartrazine may influence the ocular disease. 
 
Family history/Co-morbidity. Many patients have a history of other allergic diseases 
or the family has a history of other atopic diseases. Allergic conjunctivitis or 
conjunctival symptoms are present in 30-71% of patients with allergic rhinitis (10). 
Allergic conjunctivitis alone has been estimated in 6-30% of the general population 
and in up to 30% in children alone or in association with allergic rhinitis(13).  Up to 
40-75% of VKC patients suffer from other allergic diseases like asthma, allergic 
rhinitis, atopic dermatitis or urticaria (13).  AKC is present in up to 40% of atopic 
dermatitis patients. In the active period the co-morbidity with atopic dermatitis and 
asthma is around 90% (14).  
Finally, apart from eye symptoms it may be necessary to consider the patient’s 
activity limitations, sleep problems, coexisting nose, respiratory and cutaneous 
problems but also practical and emotional aspects.  
 
Recommendations 
 Accurate medical and personal history 
 Red eye differential diagnosis 
 Always ask for ocular signs and symptoms in other allergic co-morbidities 
 Investigate triggers for signs and symptoms 
 Refer to ophthalmologist (red eye DD) 
   
 
Unmet needs 
 Primary care awareness on ocular allergy 






Clinical Ocular Examination   
 
Rationale 
Some macroscopic clinical signs can be assessed by non-ophthalmologists  (Table 3). 
Most of them are not specific for allergy and may be present in any type of 
conjunctivitis: ocular redness, conjunctival and lid edema, mucous discharge,  
The clinical diagnosis of ocular allergy thus relies on the combination of a suggestive 
medical history and signs of conjunctivitis. Some specific signs of VKC or AKC may be 
visualized by macroscopic examination, such as superior tarsal conjunctival giant 
papillae (only visible after lid eversion) and limbal inflammation with Trantas dot. 
These 2 signs may be considered as severity signs, because leading to the diagnosis 
of severe forms of OA. Lid eczema is also a very specific marker for ocular allergy.  
Examination of the ocular surface by ophthalmologists may disclose various other 
signs such as conjunctival papillar hypertrophy, follicules, or scarring, blepharitis (lid 
margin inflammation) and meibomian gland dysfunction (MGD), and tear instability. 
The 3 latter signs are important for the frequent differential diagnosis of evaporative 
dry eye related to MGD. Corneal involvement is a marker of severity and is present 
only in VKC and AKC : superficial diffuse punctate epitheliopathy, neovascularization 
and scars are non specific, whereas shield ulcers and vernal plaques are much more 
suggestive of severe allergic keratoconjunctivis.  
 
Techniques 
 Day light or direct light observation of the face, lids, lid margin, palpebral and 
bulbar conjunctiva. 
 Lid eversion provides access to the superior palpebral conjunctiva. When the 
patient looks down, pull down the superior lashes then apply a flat stick on 
the superior half of the lid. Evert the lid by pulling the lashes up.  
 More accurate ocular examination requires the use of a slit lamp and a 
biomicroscope. Corneal and conjunctival epitheliopathy are thereby assessed 




 Always look at the eyelid skin and the lid margin  
 If you don’t have a slit lamp, look at the eye using natural light where 
possible 
 Look for severity signs 








Scoring Ocular Allergy and quality of Life  
 
Rationale and Definitions   
 
For clinical practical purposes, grading systems of conjunctivitis severity have been 
proposed including questionnaires and signs and symptoms scores. Different scales 
and criteria have been used, indicating the difficulties encountered to assess either 
acute or chronic disease manifestations. Main indications for scoring ocular allergy 
signs and symptoms include the evaluation of the severity of the disease, the 
assessment of the response to provocation tests (CPT and NPT) (see below) and the 
evaluation of the efficacy of therapeutic agents. Thus scores can be repeated during 
the follow-up of ocular allergy. 
Health related quality of life (QoL) has been defined as “the functional effects of an 
illness and its consequent therapy upon a patient, as perceived by the patient”. OA 
may significantly impact daily activities and occupations like reading, computer or 
tablet use, recreation, games, sports, television, movies, electronics.These 
disturbances generate worries, anxiety and some psychological discomfort for the 
patient, mostly for children and family. QoL instruments aim to describe these 
effects. The impact of OA on daily tasks, work, leisure, sleep and mood as perceived 
by the patient is important to consider, as a marker of severity. To date, no specific 
quality of life (QoL) questionnaire has been validated for OA, except in VKC. The 
reason might be the differences in symptoms and impacts on QoL between SAC, 
PAC, AKC and VKC. In terms of important patient-reported outcomes, the ocular 







1. Grading Signs and Symptoms 
 
The VAS is a useful alternative semi-quantitative method to express the intensity of 
symptoms by the patients. The recording is performed on a 100-mm scale without 
marked intervals by indicating the most severe symptoms on the far right and the 
absence of symptoms on the far left. The recording is explained to the study 
participants by a study clinician, but the VAS should be self-administered by the 
patients. The VAS scale is particularly used in clinical research (31). The severity of 
subjective symptoms may be ranged from (0) to (10). The slit lamp findings can be 
scored according to severity from (0) to (3): a grade of (0) is scored for no signs, (1) 
for “mild”, (2) for “moderate” and (3) when “severe” signs or symptoms are present.  
Grading questionnaires 
In the OSDI questionnaire, the score is based on the duration of symptoms. The 
score is 0 if the symptom is absent, 1 if present “some of the time”, 2 if present “half 
of the time”, 3 if present “most of the time”, and 4 if recorded “all the time”. In the 
QUICK questionnaire (18), the score is defined as : a three-point scale: 1 = never, 2 = 
sometimes, and 3 = always. The total score obtained as the sum of scores recorded 
for the different individual symptoms included in the evaluation determines the 
status of the disease.  
Ocular Severity scores  
The “Severity Index”-system is based on the subjective assessment of the patient 
regarding the grade of severity of each particular symptom and its evolution. In this 
SI-system, the score of (3) is recorded for “severe” manifestations, a score of (2) for 
“moderate” manifestations, a score of (1) for ‘’mild’’ manifestations and a score of 
(0) for the situation where no specific symptom is manifested. The status of disease 
with the SI scoring system is determined by the sum of the recorded scores for the 
individual symptoms included in the evaluation (Table). In 2012 the EAACI Ocular 
Allergy Position Paper (1, 32) proposed a severity classification of OA disorders based 
on ARIA guideline criteria (32)(5,6). The selected items are quoted “yes” or “no” for  
vision disturbance, impairment of daily activities/ leisure/ sport, impairment of 
school or work activities, troublesome symptoms. According with the number of 
items affected the OA is considered “mild” (0 items affected), “moderate” (1 item 
affected) or “severe” (2-4 items affected).  
2. Scores for therapeutic agents evaluation 
To evaluate the efficacy of new pharmacologic agents on rhinoconjunctivitis, it has 
been suggested to use either adjusted form of symptoms score (symptom score 
adjusted for the use of rescue medication), or a combined score consisting typically 
of a (weighted) sum of symptoms and rescue medication scores (RMSs) (33). 
For clinical trials on the efficacy of immunotherapy in allergic rhino conjunctivitis, 
measurements of both symptoms and the use of rescue medication (34, 35) are 
needed. The Average Combined Score (ACS) calculated is the average of the rhino 
conjunctivitis total symptom score (ARTSS) and the average rhino conjunctivitis 
medication score (ARMS). It should be considered as a primary efficacy variable for 
allergic rhino conjunctivitis in clinical trials on immunotherapy (33, 34). The ACS 
(WAO) has a range from 0 to 3, taking into account the stepwise regimen of the 
three categories of rescue medication used. Thus higher classes of rescue medication 
used lead to a higher ARMS and so to a higher ACS (WAO) (34). Rhino conjunctivitis 
allergy-control SCORE  (RC-ACS) assesses the severity of nasal and ocular allergy by 
considering symptoms and use of anti-allergic medications (36). It includes a full list 
of relevant drugs, without exclusion. Each score can be used separately or in 
combination. Thus, RC-ACS can be used in daily practice to grade real-life situations.  
 
3. Quality of life evaluation and questionnaires 
QoL questionnaires 
Generic QoL questionnaires assess global health status in a general population. The 
most frequently used scales are: the Short form 36 and 20 (SF-36 and SF-20), the 
EuroQoL (EQ-5D), and the Sickness Impact Profile (SIP) (16). The KINDL questionnaire 
is dedicated to children (17).  
 
QoL in OA 
In the absence of specific questionnaires for OA, questionnaires validated for allergic 
rhino conjunctivitis are used. The Juniper’s Rhinoconjunctivitis Quality of Life 
Questionnaire (RQLQ) (19) and its shortened version, the mini RQLQ (20), are the 
most commonly used questionnaires in adult patients. The RQLQ includes 28 items 
divided in 8 domains. The mini RQLQ has been reduced to 14 items and 5 domains : 
activity limitations, practical problems, nose symptoms, eye symptoms, other 
symptoms. Juniper et al have also developed specific questionnaires adolescents and 
children (21, 22). Ocular allergy is addressed in five symptoms in the RQLQ and 4 in 
the mini RQLQ : need to rub nose/eyes, itchy eyes, sore eyes, watery eyes, and 
swollen eyes (not in the RQLQ). Interestingly, the analysis of 4 clinical trials revealed 
that, among the 28 RQLQ items, the highest scoring items were the need to rub 
eye/nose and itchy eyes (20). In a large cohort of 1009 rhinitis patients, the presence 
of ocular symptoms statistically increased the RQLQ score by +0.5 (23).  
Among OA, VKC and AKC should probably be considered separately, because the 
impact on the patients QoL is often intense. Moreover some ocular symptoms 
related to keratitis, such as photophobia and mucous discharge, are severity 
symptoms. Sacchetti et al developed a specific QoL questionnaire for VKC patients, 
the QUICK(18). It contains 16 items, pooled in 2 domains: symptoms and daily 
activities. In contrast to children with rhinoconjunctivitis (22), daily activities like 
going to the swimming pool, practicing sports of meeting friends, were show to 
impact dramatically QoL in children affected by VKC. The QUICK questionnaire 
showed good correlation with the generic KINDL QoL questionnaire. It has been 
validated for children aged 5 to 12, and is available in Italian and English (ref). 
 
Eye-related QoLs, OA excluded. 
Some questionnaires have been developed for dry eye patients, such as the Ocular 
Surface Disease Index (OSDI) and the impact of dry eye on everyday life (IDEEL). Even 
not specifically addressed to ocular allergy, they may be interesting in order to 
assess the dry eye components in PAC for example. 
 
Impact on economic costs. 
Considering the prominence of computer monitors and visual tasks in the modern 
workplace, the effects of ocular symptoms on productivity are of great concern. 
SAC patients experienced QoL reductions in general health and specific aspects of 
vision, but also a significant economic cost to treat their condition when assessed by 
the Health Economic and Demographic Questionnaire (HEDQ)(24). This aspect must 
be taken into account for both private and public health care modalities when 
attempting to ascribe a total cost to a medical condition. Visual function can also be 




 Scoring signs and symptoms is recommended for diagnosis and monitoring  
 VAS scoring system, widely used in clinical research, gives the patients’ 
perspective  
 Consider an assessment of impact of ocular allergy on QoL, however a 
specific questionnaire is missing 
 The EuroQoL (EQ-5D) gives at least the basic information on general QoL 
 In the absence of a specific questionnaire on ocular allergy the miniRQLQ can 
be used  
 The QUICK is the only specific and validated questionnaire for VKC 
 
Unmet needs 
 Universal, definitive severity scoring syste 
 Correlation among currently available severity scoring systems is still 
unknown 
 Specific QoL questionnaires should be developed to study ocular allergy 
impact on vision, general and psychological condition in different ages 
 The ideal tool could measure disease and symptoms perception and 







Tests to diagnose ocular allergy   
 
Rationale and definitions 
In the diagnostic process of OA, the allergen may be considered as either the main 
factor triggering symptoms, closely associated with non-allergenic factors, or 
unrelated to clinical symptoms. Allergens account for the main inflammatory 
mechanisms on the ocular surface, by triggering the cascade of IgE mediated allergy.  
Currently, skin prick tests (SPT) are unanimously considered the gold standard and 
the first-line approach to detect IgE mediated sensitization, due to its efficiency, 
safety and relatively low costs (37). The biological assays are considered a second 
choice, to be used only in special situations. Once sensitization is demonstrated, its 
relevance for the patient should be investigated. The specific conjunctival 
provocation (CPT) should be considered, particularly when polysensitization is 
evidenced or in cases when clinical history is suggestive of ocular allergic reaction 
but SPT and IgE are negative or inconclusive (1) (Fauquert submitted).  
IgE mediated investigation is indicated in the majority of cases of SAC and PAC. The 
relationship between allergen sensitization and the allergen exposure is easy to 
assess in many case, particularly of SAC. However allergic investigation may not be 
necessary in cases where symptoms resolve with symptomatic treatment, or when 
symptoms occur after an obvious allergen exposure. Conversely, when symptoms 
persist (PAC) or repeat (SAC) regardless of treatment, allergic investigation is 
needed. VKC and AKC require IgE mediated investigation and, when medical history 
point towards contact allergy, non IgE mediated data. Not IgE mediated allergy can 
also account for some cases of contact blepharoconjunctivitis, and also in some 






The skin prick test (SPT) technique is currently considered the gold standard method 
for the diagnosis of IgE mediated allergen sensitization. SPT should be performed 
with airway and some food allergens, and read according to a rigorous methodology 
following the EAACI recommendations (38). Indications of intradermal tests are 
limited to selected cases and allergens. Patch-tests aim to explore non IgE mediated 
allergy (Brasch 2014). Haptens involved may be preservatives or additives of eye 
drops, cosmetics, or professional allergens. Most of time, the European battery is 
tested in addition to cosmetics or eye drops used by the patient. 
 
Specific IgE measurements 
The method most frequently used to measure serum allergen-specific IgE is an 
immune-enzymatic assay. In vitro IgE sensitization is assessed over 0.1 IU/mL 
although low serum levels (< 0.35 IU/mL) of specific IgE are less likely to be clinically 
relevant. Measurements of specific IgE are less sensitive than SPT (39, 40) and not 
mandatory when SPT correlate with the clinical history. The presence or absence of 
specific IgE in the serum does not imply a clinically relevant allergy. Local 
sensitization is highly suspected in the eye (41). In such cases, microarray 
measurements of specific IgE in a small quantity of tear could be helpful in the near 
future (38). Total IgE level is not recommended for allergy diagnosis since its 
variations significantly correlate with atopic background. Comparing the serum and 
tear total IgE dosages could be considered as an indirect method for assessing local 
release of IgE and thus for evidencing local allergy (42).   
 
Conjunctival provocation test (CPT) 
CPT, also known as conjunctival allergen challenge (CAC) or ocular challenge test, is 
used to evaluate the inflammatory effects on the ocular surface after the topical 
application of an allergen (1). Thus allergen sensitization must be evidenced before 
performing instillation of allergen, unless the exposure environment is convincing of 
allergy but no sensitization is assessed (43). Recommendations were published 
recently on behalf of the EAACI (PP Fauquert submitted and 39). A positive CPT 
triggers the same symptoms (itching and tearing) and signs (redness, chemosis and 
lid swelling) as those of a natural exposure to the allergen. Contraindications are 
limited to uncontrolled allergic and chronic diseases as well as acute impairment of 
the ocular surface. In daily practice, it requires an informed consent, an 
ophthalmologic examination to rule out any inflammation of the ocular surface in a 
clinic able to manage side-effects, and a controlled protocol based on precise 
positivity criteria. Itching and redness are the main criteria to achieve a positive 
response when score 2+ (30). The IGOA Task Force on CPT in daily practice 
recommend to assess the reproducibility of the provocation test, the use of total 
ocular symptom score (TOSS; range 0 -13), including subjective plus objective 
criteria, to be considered positive when the cumulative scoring reaches 5 (Table 2) 
(PP Fauquert Submitted). Monitoring of both early and late allergic response should 
be considered. Since allergic response to CPT may induce both ocular and nasal 
symptoms, scoring of nasal symptoms is useful.  Conversely a NPT is considered 
positive when the cumulative symptoms score of the 4 classical nasal symptoms - 
Linder Symptom Score Scale (LSSS; range 0-13) - is equal or higher than 5 points (33).  
However there is a lack of a standardized method for evaluating the combined 
ocular and nasal symptoms in response to CPT or NPT. Despite the safety of this 
simple and fast tool to assess ocular or other IgE-mediated allergic diseases, it is 
clearly underused in daily clinical practice. Nonspecific challenge tests are only used 
for research purposes (39). 
 
Recommendations  
 If results of skin prick test, IgE levels and allergen exposure history are in 
concordance, the involvement of the allergen can be assumed.  
 Otherwise CPT should be considered, particularly if multiple sensitizations are 
suspected.  
 CPT is recommended when medical history suggests an allergen, even if SPT 
are negative 
 In VKC and AKC, allergen-specific triggering is less frequently involved.  
 When contact blepharitis or blepharo-conjunctivitis is suspected, patch-tests 
are required.  
 
Unmet needs 
 There is a lack of a standardized method for evaluating the combined ocular 
and nasal symptoms in response to CPT or NPT.  





Assessing consequences of OA 
 
Psycho environmental consequences 
Rationale and  
 
 
Visual Function  
 
Rationale 
Allergic Conjunctivitis is usually not considered as a sight-threatening disorder. Its 
clinical presentation ranges from mild forms not (or slightly) influencing VF to severe 
diseases (VKC and AKC), which affect the ocular structures, visual acuity (VA) and 
QoL. Complications (corneal impairment, irregular astigmatism and scars, 
keratoconus, cataract, steroid-induced glaucoma) result in visual impairment (25). 
Visual disturbances are also caused by symptoms (intense itching, watering, foreign 
body sensation, mucus discharge, eyelid pseudo-ptosis, ocular pain and 
photophobia). Few population-based data on VA testing and impairment in OA are 
available since VA rarely represents a primary or secondary outcome of therapy in 
clinical trials.  
 
Definition 
VA “is a measure of the spatial resolution of the visual processing system” which 
means the ability to discriminate in the space two separated stimuli in conditions of 
high contrast to the background, which is determined by a comparison with the 
normal ability to define certain letters at a given distance, usually 20 feet (6 meters).  
 
Techniques 
In normal clinical practice, VA is measured by asking the subject to discriminate 
letters of known visual angle (Snellen and derived optotypes) or letters of equal 
recognition difficulty, and use the log of the minimal angle of resolution at a given 
distance and at high contrast (ETDRS and similar). Measurement of VA follows a 
psychophysical procedure and can be performed by using an eye chart, by optical 
instruments, or by computerized tests, with standard conditions, like correct 
luminance of the eye chart, correct viewing distance, enough time for responding, 
etc.  
Electronic VA testers are more comfortable in infants, pre-verbal children and special 
populations (for instance, handicapped individuals). 
Although the value of vision sometimes is difficult to measure in VKC and AKC during 
acute phases, visual QoL can be quantified as a surrogate criterion (26).  
A study on the best-corrected VA in subjects suffering from VKC shield ulcers showed 
that, after ulcer re-epithelization, VA improvement depends on the severity of shield 
ulcers (27).  
Adequate time and attention should be given to take a complete and accurate VA 
examination. All VKC and AKC patients should routinely undergo topographic corneal 
assessment because of the higher incidence of keratoconus in atopic diseases (28, 
29). Association between OA and KC…. 
 
Recommendations 
 Consider VA assessment as a primary outcome in daily practice 
 VKC and AKC subjects should undergo topographic corneal examination to 
rule out keratoconus 
 
 
Ocular surface evaluation (Tear film function) 
 
Rational  
Chronic conjunctival allergy is a cause of evaporative dry eye. Simple tear film 
evaluating tests …. 
 
Definition  
 Dry eye is classified as hypo-secretory or evaporative.  
 Schirmer test quantifies the tear secretion, whereas break-up time (BUT) 
assesses tear film stability.  
 Tear hyper-osmolarity is a marker of dry eye.  
 Low tear lipid layer thickness is related to meibomian gland dysfunction 




Invasive BUT (O): Insert a wetted fluorescein strip in the inferior conjunctival fornix, 
and remove when tears are stained. Use blue cobalt light +/- yellow filter for 
observation. After a few blinks, ask patient not to blink and measure time between 
the last complete blink and tear film break (when black striae appear in the 
precorneal tear film). Repeat measure 3 times. Mean values below 10 seconds 
reflect tear instability and evaporative dry eye(44). 
 
Non invasive BUT – NIBUT (NO): Some specific devices like some corneal topographs, 
aberrometers, measure NIBUT. 
 
Schirmer test 
Insert a nitrocellulose Schirmer strip into the inferior conjunctival fornix, at the 
external third of the inferior lid. Measure the length of wetted strip within 5 
minutes. A test without anesthesia is recommended as being more reproducible. 
Values below 5 mm reflect aqueous deficient dry eye(44). 
 
Tear osmolarity can be measured by an osmolarimeter, after tear sampling. The 
Tearlab® device provides an immediate result after automated collection of a few 
nanoliters. Values beyond 312 mOsm/L are abnormal. 
 
Tear lipid layer thickness can be measured by interferometers like the Lipiview® 
(Tearscience) or the DR1® (Kowa).  
 
Recommendations 
 Consider that tear film dysfunction can be caused by OA. 




Ocular Sampling    
 
Rational and definition 
Samples can be easily obtained from the ocular surface making cytological tests and 
mediator search an attractive tool in OA.  
 
Technique 
Different methods for tear collection can be used: capillary tube, filter paper, 
ophthalmic sponges and eye washes (45).  
Aspiration of tears by glass capillary tubes or pipettes can yield volumes of 20–50 μl. 
However tear collection is tedious, time-consuming, and sometimes uncomfortable 
for patients and children, and may provoke the production of reflex tears by 
touching the conjunctiva with the capillary (46, 47). Tears can be recovered from a 
Schirmer’s strip which is routinely used in the ophthalmology clinic as a standard 
clinical test to assess the tear quantity in patients with dry eye syndrome (see 
above). Strips tend to collect some cellular proteins which may come from epithelial 
conjunctival cells, moreover tear reflex is common due to strong irritation by the 
strip (48). Various sponges (cellulose sponges, porous polyester rods, polyurethane 
mini sponges, cellulose acetate filter rods) can be placed in the lower tear meniscus 
and held for a fixed period of time (49, 50). For the eye wash technique, a fixed 
volume of saline is instilled into the inferior fornix and the fluid collected by a 
capillary tube (51). It may be useful where the tear volume is very low, however it is 
impossible to determine the original tear volume and the dilution of proteins.   
 
Recommendations 
 It is preferable to collect samples independently from both eyes since in 
many cases there is an asymmetrical clinical presentation.  
 Capillary tube collection is preferable since cells and mediators may bind to 
the strips or sponges, and diffusing cytokines out of the device during the 




Tear biomarkers    
 
Rational and definition 
The tear fluid is an extremely complex biological mixture containing cells, 
proteins/peptides, electrolytes, lipids, and small molecule metabolites, which can be 
measured for diagnostic, prognostic and experimental purposes. Tear collection is 
not painful or traumatic, with only its insurmountable limitation regarding the 
quantity of sample obtainable. The challenge in the analysis of tear fluid is the high 
dynamic character of the tear proteome, and the small sample size, therefore the 
total amount of proteins that can be used for analysis is low when compared with 
blood. Tear protein analysis was limited to a few analytical techniques dependent on 
antibody availability. With increasing proteomic applications, tears show great 
potential as a source of biomarkers in the development of clinical assays for various 
human diseases. The concentration and distribution of proteins and inflammatory 
mediators in tears have been extensively used in OA to find either a ‘disease 
marker’, to understand better the immune mechanisms involved in the ocular 




A cytological test can be performed using tears, conjunctival scrapings, impression 
cytology or conjunctival biopsy. For tear cytology, a few microlitres of tears collected 
from the external canthus with a glass capillary are immediately placed on a slide.  
Conjunctival scrapings, performed with a spatula or a brush, allow for the collection 
of a good amount of epithelial and inflammatory cells (if present). Pre-colored slides, 
or rapid dyes can be used for a response in a short time. Impression cytology refers 
to the application of cellulose acetate filter to the ocular surface to remove the 
superficial layers of the ocular surface epithelium (52). Conjunctival biopsy 
(performed under topical anesthesia) is required when a neoplastic pathology or 
autoimmune diseases is suspected. Papanicolaou or haematoxylin and PAS stains are 
the commonly used stains for routine histological staining of specimens. Samples can 
be also used for different immunostaining, flow cytometry techniques, RNA or DNA 
extraction, all depending on the number of cells collected. 
In patients with allergic conjunctivitis, the cellular constitution of the tear film is 
characterized by the presence of neutrophils, eosinophils and lymphocytes (53). A 
secondary immediate, late and delayed conjunctival responses, induced by the nasal 
provocation test with allergen (NPT), were associated with different cellular profiles 
in the tears (54). By flow cytometry, the percentages of T cells, activated B cells, and 
T-helper/T-suppressor cell ratios were found to be higher in tears of patients with 
AKC than in controls (55). Using intra-cytoplasmic cytokine expression, an increase in 
Th2 lymphocytes in tear fluids of patients with VKC has been demonstrated (56). 
 
Tear protein analysis 
Total protein concentration decreases significantly if the tear samples are kept at 
room temperature for 4-8 h and further drops to 70-80% of the original 
concentration after 16 h (57). Tear samples can be kept up to one week at 4˚C, up to 
2 months at -20 ˚C, and up to 4 months at -70˚C with very small loss of protein (58). 
 As tears contain various enzymes and hydrolases, proper storage of tear 
samples is an important issue to prevent sample loss and unreliable results. 
(move to text) 
 The ultimate outcome could be affected by the tear collection method 
chosen and the consistency of the extraction protocol making it difficult to 
assess the feasibility of the protocols and to compare the results between 
different studies (49).   (text) 
 
Dozens of mediators, cytokines, chemokines, growth factors, angiogenic modulators, 
proteases, enzymes and inhibitors have been identified in small tear samples using 
new methods such as multiplex bead arrays, membrane-bound antibody array and 
proteomic techniques in addition to the traditional ELISA or RIA (59).  
Total and specific IgE have been measured in tears to improve the diagnosis of IgE-
mediated allergic conjunctivitis (41). Patients with high total tear IgE have a high 
probability of allergic sensitization, however measurement of tear allergen-specific 
IgE antibodies is a more specific diagnostic maker of allergic sensitization (42, 59). 
The increased tear concentrations of tryptase and histamine have been considered 
biomarkers of allergic conjunctival response (see for review(59)). 
The measurement of eosinophil cationic protein (ECP) in tears has been considered a 
valid tool in monitoring ocular allergic diseases, and in the evaluation of topical 
therapies (60-62). Although several cytokines, chemokines and their receptors have 
been found over-expressed in allergic ocular inflammations, none of them seems to 
be ideal to be used as clinical biomarker (59). 
Proteomic analysis of tear fluid has proven to be a promising approach to gain more 
information about the pathogenesis of diseases and lead to new diagnostic 
possibilities. Increased hemopexin concentration in VKC tears was found to be 
significantly associated with disease severity (63). Levels of serum albumin, 
transferrin and hemopexin were found up to 100 times higher in VKC tears than 
controls and correlated to the severity of disease (64). In addition, hemopexin, 
transferrin, mammaglobin B, and secretoglobin 1D were found significantly 
overexpressed in VKC samples compared with the control samples (64). 
Excluding assays for total IgE and MMP-9 specifically designed for tears, no local 
tests have been standardized for clinical use and probably no single factor or test is 
considered as a specific disease marker.  
More likely, a combination of several of them may be required to indicate a single 




 The presence of even one eosinophil in cytology is highly indicative of an 
allergic pathology, whereas their absence does not exclude an allergic 
diagnosis 
 Tear collection and storage can influence biomarker detection 
 
Unmet need 
 One possibility would be to design an assay kit to detect a panel of tear 
markers, including total IgE, tryptase, eotaxin, ECP, IL-4, IL-5, MMP-9 which 
have been found consistently increased in ocular allergic diseases and 




Imaging and emerging additional tests    
 
Rational 
In-vivo imaging technologies including in-vivo confocal microscopy, meibography, 
tear film interferometry and photography have been widely used in the diagnosis, 
assessment of clinical severity and follow-up of ocular surface disorders. The 
application of these technologies to detect the pathological alterations in the 
conjunctival epithelium, cornea, meibomian glands (MG) and the tear film structure 
related to OA may help to quantify the extent of inflammation and evaluate the 
efficacy of allergic agents. 
 
Definition and Techniques 
In-vivo Confocal Microscopy (IVCM) is a real-time, in vivo, non-invasive imaging 
technology, which enables microstructural analysis of cornea in more physiological 
conditions at a cellular level  (65). In contrast to conventional microscopes, which are 
limited by light scatter from structures outside of the focal plane, IVCM create a 
point source of light by a pinhole aperture, focused by an objective lens on the 
tissue. The light reflected by the tissue is then collected by a parallel objective lens, 
focused onto a separate pinhole aperture, and collected by a detector. Compared to 
traditional slit lamp imaging, IVCM provides a higher magnification and depth of 
view, but examine only a limited area. With the more recent introduction of the in-
vivo laser scanning confocal microscope (LSCM), it became possible to study the 
microscopic anatomy of translucent and semi-opaque structures, such as the 
conjunctiva and meibomian glands (MG) (66, 67). 
 
Clinical Applications in Ocular Allergic Diseases 
To identify the morphological changes in cellular and neural structures in cornea and 
conjunctiva. In VKC, cornea imaging with LSCM showed increased diameter, 
reflectivity, and presence of nuclear activation of superficial epithelial cells, lower 
density of keratocytes, increased presence of activated keratocytes, and 
inflammatory cells in the anterior stroma in close proximity to the subbasal and 
stromal nerve fibers (68). Infiltration of Langerhans cells and inflammatory cells in 
epithelium and stroma, and the destruction of Vogt Palisades were found at the 
limbus (69). Similar findings were described In AKC, where the densities of cornea 
basal epithelial cells, subbasal long nerve fibers and total nerve branches were found 
to be lower than normal eyes (70). Polymorphic and dendritic cell densities in the 
conjunctiva and cornea were found to be significantly higher compared with healthy 
control subjects which correlated well with the number of inflammatory cell 
numbers in brush cytology (71, 72). 
Cell density of the mucocutaneous junction epithelium, MG acinar unit density and 
diameter, glandular orifice diameters, meibum secretion reflectivity, and appearance 
of the glandular interstice and acinar wall, were all found significantly worse in AKC 
patients compared to obstructive MG dysfunction patients and controls (73). 
 
Clinical Applications in the CAC model 
Following CAC, IVCM can be used to track the progress of the acute allergic response 
and the subsequent ocular late phase inflammation, capturing video images useful 
to study dynamic events, such as leukocyte-endothelial cell rolling and arrest in 
human ocular vessels overlying sites of inflammation (74). Increased numbers of 
white cells within the vasculature adhering to vessel wall or in process of diapedesis 
were shown after CAC (75). A conjunctival inflammation confocal scale (0-4) (patent 
pending), to grade the leukocyte presence and adhesion in and around the 
conjunctival blood vessels has been proposed. 
This may become particularly useful to evaluate the efficacy of allergic medications 
in terms of presence of inflammatory cells in the conjunctiva and cornea as well as in 
measuring changes in epithelial integrity and papillae pathology. In AKC patients, the 
addition of topical cyclosporine A (CsA) to topical steroid and anti-allergic treatment 
showed a significantly lower density of inflammatory cells and remarkable fibrosis in 
papillae (76). Similarly, after a 3-month treatment, topical CsA reduced the number 
of conjunctival, limbal and peripheral cornea DCs in VKC patients (77). 
 
 
Meibography is a non-invasive technique developed to observe the structure of MG 
in silhouette, by illuminating the eyelids from the skin side, and can detect their 
morphological changes. There are two techniques: contact and non-contact using 
either a light probe directly applied onto the eyelid or infrared (IR) filter and IR 
charge-coupled device video camera (78, 79). The evolution of meibography has 
recently accelerated with the advent of non-IR technologies including laser confocal 
meibography and OCT meibography (67, 73, 80-82).(reference 83 might be excluded) 
 
Clinical Applications in Ocular Allergy 
MG shortening, distortion and dropout may be observed easily. PAC and contact lens 
associated allergic conjunctivitis were found to be associated with increased MG 
duct distortion in half of the patients (83, 84). 
 
Lipid Layer Interferometry measures tear stability by imaging the surface contour of 
the tear film and analyzes the depth or ‘‘thickness’’ of the lipid layer. Normally, a 
thick lipid layer spans the tear surface in a continuous manner, whereas a thin lipid 
layer degenerates into discontinuous patchy regions denoting an unstable tear film 
(85, 86). 
 
Clinical Applications in Ocular Allergy 
Seventy-eight percent of SAC patients were found to have an advanced tear 
instability and thickening of the tear film lipid layer with changes similar to those 
typical of dry eye (87).  
 
Photography: Clinical evaluation of conjunctival hyperemia is subjective, and relies 
on grading scales ranging from 0-5 (88-90). Conjunctival hyperemia can be evaluated 
by the observer on the basis of digital photos using a modified grading scale or by 
using digital image analysis software. Digital image analysis is an objective evaluation 
method compared to the subjective evaluation by the investigators (91-96). 
Threshold-setting, edge-detection, color extraction, smoothing, fractal analysis or 
densitometry techniques are used in digital analysis.  
 
Clinical Applications in Ocular Allergy 
Assessment of symptom severity in allergy 
Objectifying conjunctival provocation test (CAC Models) 
Assessment of the efficacy of anti-allergic medications 
Assessment of the efficacy of immunotherapy 
 
Recommendations 
 Emerging imaging technologies have potential roles in evaluating ocular 
surface changes in OA.  
 New techniques may enable the clinician to estimate the degree of the 
inflammation helping in better diagnosis, follow-up and treatment of allergic 
process.  
 Future widespread employment of these techniques supplementary to the 





Unmet needs in the diagnostic tools 
 Specific questionnaires on medical history for ocular allergy 
 It is still not clear why the eye can be the only target organ, or why some 
patients suffer from severe untreatable or chronic forms 
 Specific mediator and cellular mechanisms associated with particular types of 















Table 1. Clinical features of major ocular allergy syndromes, including the underlying 
hypersensitivity mechanism and ophthalmological presentation (Allergy 2012). 
 SAC PAC VKC AKC GPC CBC 
Presentation Intermittent Persistent Persistent ± 
intermittent 
exacerbations 

















Background Atopic Atopic Childhood ± 
atopic 





























± Tranta’s dots 
Hyperemia - 
Cornea - - 
 
SPK 









SAC=seasonal allergic conjunctivitis; PAC=perennial allergic conjunctivitis; VKC=vernal 
keratoconjunctivitis; AKC=atopic keratoconjunctivitis; GPC=giant papillary conjunctivitis; CBC=contact 







Table 2 Relevant signs related in clinical ocular examination 
 





Form of OA Non allergic forms/ 
Differential diagnosis 
Signs assessable by a non ophthamologist 
Conjunctival 
redness 






Yes ++++ VKC, AKC GPC 
Limbal 
inflammation 
Yes ++++ VKC, AKC Limbal tumor 
Chemosis, lid 
edema 
 + All Non allergic 
conjunctivitis 
Mucus discharge  ++ All, especially VKC, 
AKC 
Infection, severe dry 
eye, GPC 
Lid eczema  ++++ AKC, CBC, VKC Seborrhoeic 
dermatitis, psoriasis, 
lid molluscum 
Blepharitis   All Rosacea, seborrhoeic 
dermatitis 
Signs only assessable by an ophthamologist 
Conjunctival 
papillae 
 +++ All Bacterial conjunctivitis, 
rosacea, dry eye 
Conjunctival 
follicules 










Yes  VKC, AKC Non allergic keratitis 
Corneal shield ulcer 
or plaque 
Yes ++++ VKC, AKC None 
Tear instability   PAC > AKC, VKC Rosacea, non allergic 
tear instability 
 
OA= Ocular allergy; SAC=seasonal allergic conjunctivitis; PAC= perennial allergic conjunctivitis; VKC= 




Table 4.  Scoring system in ocular allergy (including CPT) 
 
Itching 
0 = none 
1 = mild (intermittent itching sensation) 
2 = moderate (continual awareness but without the desire to rub) 
3 = severe (continual awareness with the desire to rub the eyes) 
4 = incapacitating itching (subject insists on rubbing eyes). 
 
Redness 
0 = none 
1 = mild (perhaps localized within some quadrant) 
2 = moderate (more marked and diffuse reddening in the quadrants) 
3 = severe (very marked and diffuse reddening in the quadrants).  
 
Tearing 
0 = none 
1 = mild (slightly humid eye) 
2 = moderate (some tears, blows nose occasionally) 
3 = severe (profuse tearing, tears rolling down cheeks) 
 
Chemosis 
0 = none 
1 = mild (detectable with slit lamp, conjunctiva raised from sclera) 
2 = moderate (visually evident, raised conjunctiva, especially at the limbal area)  




grade 1: ulcers that extend the Bowman’s membrane and yet have a transparent base 
grade 2: ulcers that have an opaque base and are partially filled with inflammatory debris 
grade 3: ulcers filled with debris (plaque) that remain above the surrounding epithelium 
 
Table xxx. Recommendations for diagnostic tools in ocular allergy (draft #2) 
Check Rec in each chapter 
 
 Aims Methods 
/Instruments 
Recommendations 
History Evaluation of: 
-Symptoms and severity 
-Co-morbidities and general 
-Medical condition 
-Medical/surgical history 
-Exposure to allergens/ 
irritants/ non specific 
triggers 
-Visual tasks 
-Talk to patients and 
parents 
-Questionnaires 
•Accurate medical and personal history 
•Red eye differential diagnosis 
•Always ask for ocular signs and symptoms in 
other allergic co-morbidities 
•Investigate triggers for signs and symptoms 
•Refer to ophthalmologist (red eye DD) 
 
QoL  -To assess the effects of 
disease on daily 
 functioning, work, leisure 
and school perceived by 
patient 
-Questionnaires •Consider an assessment of impact of ocular 
allergy on QoL, however a specific 
questionnaire is missing 
•The EuroQoL (EQ-5D) gives at least the basic 
information on general QoL 
•In the absence of a specific questionnaire on 
ocular allergy the miniRQLQ can be used  
•The QUICK is the only specific and validated 




-To assess specific and non 
specific signs  
-Observation with and 
without the slit lamp 
 
Visual function -To assess best VA -Optotypes •Consider VA assessment as a primary 
outcome in daily practice 
•VKC and AKC subjects should undergo 
topographic corneal examination to rule out 
keratoconus 
 
S&S Scores evaluation of: 
-severity of the disease  
-CPT and NOT response 
-efficacy of treatments 
-grading syspems  
Allergy Test -Evaluation of the specific 
sensitization state and  
 
-Skin prick test 
-Blood analysis with 
allergen-specific IgE 
 
-PATCH test  
-Recommended in all patients with clinical 
suspicion of IgE allergic disease 
 
 
-Recommended in all patients with clinical 
suspicion of contact and eyedrop allergy 
Conjunctival 
Provocation Test 
-Evaluation of the 
conjunctival response to 
specific allergens  
-Provocation by 
topical allergen at 
fixed solutions 
-In case of negative SPT /sIgE  
-Polysensitized patients 
-To evaluate desensitization 
 
Tear film function -Evaluate tear film stability, 




-Meibomian gland  
- 
 
-In all patients with chronic allergy 
-When adverse environment cause symptoms 
 
Ocular sampling -Obtain tear fluids, cells, 






-Cytology for qualitative inflammation 
-In experimental and clinical studies 
-Biopsy in case of autoimmune diseases and 
unilateral/malignant disease 






-Diagnostic tools in severe cases 
- 
Imaging -To evaluate corneal cells, 
nerves and stroma 







-In experimental and clinical studies 
 




RC-ACS Symptom score 
 7 symptoms 
 3 ocular: itching, tearing, redness 
 4 nasal: sneezing, itching, running, blockage 
 
 Scale ranging from 0 to 3:  
 0 = absent (no sign/ symptom evident) 
 1 = mild (sign/symptom clearly present, but minimal awareness; easily 
tolerated) 
 2 = moderate (definite awareness of sign/symptom that is bothersome, 
but tolerable) 
 3 = severe (sign/symptom that is hard to tolerate; causes interference 
with activities of daily living and/or sleeping) 
 
The maximum total number of “score points” (SP) for symptoms on one day is 21 (7 
x 3)   
 
Rhino-Conjunctivitis Allergy-Control-Score (RC- ACS) 
 
 
 Annex 2 
 
RC-ACS Medication score 
 
Categories of medication included: 
 Nasal medication: 
o anti-histamines, glucocorticoids, decongestants, mast cell stabilizers, 
and salts 
 Ocular medication: 
o anti-histamines,  mast cell stabilizers, decongestants, glucocorticoids, 
lubricants 
 Systemic medication: 
o antihistamines, glucocorticoids and their combinations, leukotriene 
receptor antagonists. 
 Drugs not foreseen by international Guidelines for treating allergic rhino-
conjunctivitis are not included (e.g. anti- IgE) 
 
The total SP for  medication is also 21:  
–nose sub-score (max. 12 SP)  
–eyes (max. 9 SP)    
 
Rhino-Conjunctivitis Allergy-Control-Score (RC- ACS) 
The total number of “score points” (SP) for  medication is also 21, subdivided into the two sub-scores 
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